New Strategies in Prostate Cancer: Translating Genomics into the ...

1. Himisha Beltran1,2 and
2. Mark A. Rubin1,3

1. Authors' Affiliations: ¹Weill Cornell Cancer Center; Departments of ²Medicine and ³Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York

1. Corresponding Author:
   Mark A. Rubin, Weill Medical College of Cornell University, Department of Pathology and Laboratory Medicine, 1300 York Avenue, New York, NY 10065. Phone: 212-746-6326; Fax: 212-746-8816; E-mail: rubinma{at}med.cornell.edu

With the rapidly developing use of next-generation sequencing technologies, there has been a surge in our knowledge of the genomic landscape of prostate cancer and a movement toward developing a molecular subclassification system for the disease. With this new understanding comes great clinical potential, both for the development of biomarkers as well as new therapeutic targets. Herein, we highlight the potential clinical use of recent discoveries and how they fit into our current paradigm. We describe the challenges that lie ahead as we move from genomic sequencing toward routine clinical practice and adopt precision cancer care for patients with prostate cancer. Clin Cancer Res; 19(3); 517?23. ?2012 AACR.

• Received September 6, 2012.
• Revision received November 23, 2012.
• Accepted December 9, 2012.

• ?2012 American Association for Cancer Research.

Source: http://clincancerres.aacrjournals.org/content/19/3/517.short

in plain sight hunger games movie review bats hunger games review jeff saturday jason smith jon corzine